secwatch.observer — SEC 8-K summary
======================================

Issuer:     ABVC BIOPHARMA, INC. (ABVC)
CIK:        0001173313
Form:       8-K
Filed at:   2026-08-27T12:30:29+00:00
Accession:  0001213900-26-094152
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.65
Item codes: 1.01, 2.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ABVC completes spin-off of 15% of BioKey Cayman to shareholders; retains 85% control
--------------------------------------------------------------------------------

- Distributed 4,500,390 BioKey Cayman ordinary shares (15% stake) to ABVC stockholders on Aug 21, 2026.
- Record date July 24, 2026; holders received 0.169464 BioKey share per ABVC share held.
- ABVC retains ~85% ownership; BioKey Cayman becomes independent SEC reporting company.
- BioKey Cayman intends to apply for OTC Markets listing; no trading market currently exists.
- Ancillary agreements (TSA, Tax Matters, Employee Matters) dated June 22, 2026 govern post-spin relationship.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1173313/000121390026094152/0001213900-26-094152-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1173313/000121390026094152/ea0302908-8k_abvc.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-094152

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer